Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma

Completed · Phase 2

Conditions studied: Thymoma, Thymic Carcinoma

In brief

To study the efficacy of Alimta as a single agent in thymic cancers

Key facts

Study ID

NCT00198133

Run by

Patrick Joseph Loehrer Sr.

People needed

27

Starts

2005-01-01

Expected to finish

2012-05-01

Last updated by the study team

2019-07-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed invasive, recurrent or metastatic thymoma or thymic carcinoma not amenable to potentially curative therapy by surgery. Original biopsy of tumor is sufficient for diagnoses unless otherwise clinically indicated.
• Patients must have measurable disease with at least one bidimensional measurable lesion. Any scans or x-rays used to document measurable disease must be obtained with 6 weeks prior to registration.
• Patients may have had prior chemotherapy for metastatic disease
• Adequate organ function as defined by: bili </=1.5; calc. crt clr of >/=45; hematologic-granulocytes >/=1500 \& plt >/=100K.
• Patients who are receiving a stable dose of corticosteroids for myasthenia gravis are eligible.
• ECOG performance status of 0 or 1

You may not qualify if…

• Acute intercurrent infection or complications
• pregnancy or lactating patients
• Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents for a 5-day period (8-day period for long-acting agents.
• Presence of clinically relevant third-space fluid collections that cannot be controlled by a procedure

Where it is running

• Indiana University Cancer Center — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.